Literature DB >> 19028703

Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation.

Ravinder Tammali1, Aramati B M Reddy, Kota V Ramana, J Mark Petrash, Satish K Srivastava.   

Abstract

Aldose reductase (AR; EC 1.1.1.21), an nicotinamide adenine dinucleotide phosphate-dependent aldo-keto reductase, has been shown to be involved in oxidative stress signaling initiated by inflammatory cytokines, chemokines and growth factors. Recently, we have shown that inhibition of this enzyme prevents the growth of colon cancer cells in vitro as well as in nude mice xenografts. Herein, we investigated the mediation of AR in the formation of colonic preneoplastic aberrant crypt foci (ACF) using azoxymethane (AOM)-induced colon cancer mice model. Male BALB/c mice were administrated with AOM without or with AR inhibitor, sorbinil and at the end of the protocol, all the mice were euthanized and colons were evaluated for ACF formation. Administration of sorbinil significantly lowered the number of AOM-induced ACF. Similarly, AR-null mice administered with AOM demonstrated significant resistance to ACF formation. Furthermore, inhibition of AR or knockout of AR gene in the mice significantly prevented AOM-induced expression of inducible nitric oxide synthase and cyclooxygenase-2 proteins as well as their messenger RNA. AR inhibition or knockdown also significantly decreased the phosphorylation of protein kinase C (PKC) beta2 and nuclear factor kappa binding protein as well as expression of preneoplastic marker proteins such as cyclin D1 and beta-catenin in mice colons. Our results suggest that AR mediates the formation of ACF in AOM-treated mice and thereby inhibition of AR could provide an effective chemopreventive approach for the treatment of colon cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028703      PMCID: PMC2722145          DOI: 10.1093/carcin/bgn246

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  46 in total

Review 1.  T cells orchestrate intestinal mucosal shape and integrity.

Authors:  T T MacDonald; M Bajaj-Elliott; S L Pender
Journal:  Immunol Today       Date:  1999-11

2.  Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis.

Authors:  Y Gökmen-Polar; N R Murray; M A Velasco; Z Gatalica; A P Fields
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

3.  Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells.

Authors:  Ravinder Tammali; Kota V Ramana; Sharad S Singhal; Sanjay Awasthi; Satish K Srivastava
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

4.  Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis.

Authors:  M Takahashi; M Mutoh; T Kawamori; T Sugimura; K Wakabayashi
Journal:  Carcinogenesis       Date:  2000-07       Impact factor: 4.944

5.  Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.

Authors:  Chinthalapally V Rao; Cooma Indranie; Barbara Simi; Pamela T Manning; Jane R Connor; Bandaru S Reddy
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

6.  Regulatory role of phosphatidylinositol 3-kinase on TNF-alpha-induced cyclooxygenase 2 expression in colonic epithelial cells.

Authors:  S A Weaver; M P Russo; K L Wright; G Kolios; C Jobin; D A Robertson; S G Ward
Journal:  Gastroenterology       Date:  2001-04       Impact factor: 22.682

7.  Characterization of dysplastic aberrant crypt foci in the rat colon induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

Authors:  Masako Ochiai; Mitsunori Ushigome; Kyoko Fujiwara; Tsuneyuki Ubagai; Toshihiko Kawamori; Takashi Sugimura; Minako Nagao; Hitoshi Nakagama
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

8.  Aldose reductase mediates cytotoxic signals of hyperglycemia and TNF-alpha in human lens epithelial cells.

Authors:  Kota V Ramana; Brian Friedrich; Aruni Bhatnagar; Satish K Srivastava
Journal:  FASEB J       Date:  2002-12-17       Impact factor: 5.191

9.  COX2 activity promotes organic osmolyte accumulation and adaptation of renal medullary interstitial cells to hypertonic stress.

Authors:  Gilbert W Moeckel; Li Zhang; Agnes B Fogo; Chuan-Ming Hao; Ambra Pozzi; Matthew D Breyer
Journal:  J Biol Chem       Date:  2003-03-09       Impact factor: 5.157

10.  Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells.

Authors:  Kota V Ramana; Deepak Chandra; Sanjay Srivastava; Aruni Bhatnagar; Bharat B Aggarwal; Satish K Srivastava
Journal:  J Biol Chem       Date:  2002-06-12       Impact factor: 5.157

View more
  25 in total

Review 1.  Understanding the role of aldose reductase in ocular inflammation.

Authors:  U C S Yadav; S K Srivastava; K V Ramana
Journal:  Curr Mol Med       Date:  2010-08       Impact factor: 2.222

2.  Aldose reductase inhibition prevents hypoxia-induced increase in hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) by regulating 26 S proteasome-mediated protein degradation in human colon cancer cells.

Authors:  Ravinder Tammali; Ashish Saxena; Satish K Srivastava; Kota V Ramana
Journal:  J Biol Chem       Date:  2011-05-16       Impact factor: 5.157

Review 3.  Targeting aldose reductase for the treatment of cancer.

Authors:  Ravinder Tammali; Satish K Srivastava; Kota V Ramana
Journal:  Curr Cancer Drug Targets       Date:  2011-06       Impact factor: 3.428

4.  Inhibition of aldose reductase prevents growth factor-induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells.

Authors:  Kota V Ramana; Ravinder Tammali; Satish K Srivastava
Journal:  Mol Cancer Ther       Date:  2010-03-30       Impact factor: 6.261

5.  Inhibition of aldose reductase prevents colon cancer metastasis.

Authors:  Ravinder Tammali; Aramati B M Reddy; Ashish Saxena; Piotr G Rychahou; B Mark Evers; Suimin Qiu; Sanjay Awasthi; Kota V Ramana; Satish K Srivastava
Journal:  Carcinogenesis       Date:  2011-06-03       Impact factor: 4.944

Review 6.  Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders.

Authors:  Satish K Srivastava; Umesh C S Yadav; Aramati B M Reddy; Ashish Saxena; Ravinder Tammali; Mohammad Shoeb; Naseem H Ansari; Aruni Bhatnagar; Mark J Petrash; Sanjay Srivastava; Kota V Ramana
Journal:  Chem Biol Interact       Date:  2011-02-24       Impact factor: 5.192

7.  Inhibition of aldose reductase prevents endotoxin-induced inflammation by regulating the arachidonic acid pathway in murine macrophages.

Authors:  Mohammad Shoeb; Umesh C S Yadav; Satish K Srivastava; Kota V Ramana
Journal:  Free Radic Biol Med       Date:  2011-08-05       Impact factor: 7.376

8.  Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression.

Authors:  Ashish Saxena; Mohammad Shoeb; Kota V Ramana; Satish K Srivastava
Journal:  Eur J Cancer       Date:  2013-07-01       Impact factor: 9.162

9.  Aldose Reductase Inhibitor, Fidarestat Prevents High-fat Diet-induced Intestinal Polyps in ApcMin/+ Mice.

Authors:  Ashish Saxena; Ravinder Tammali; Kota V Ramana; Satish K Srivastava
Journal:  Curr Cancer Drug Targets       Date:  2018       Impact factor: 3.428

Review 10.  Aldose reductase: a novel therapeutic target for inflammatory pathologies.

Authors:  Kota V Ramana; Satish K Srivastava
Journal:  Int J Biochem Cell Biol       Date:  2009-09-22       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.